{"id":41865,"date":"2023-11-23T16:52:10","date_gmt":"2023-11-23T16:52:10","guid":{"rendered":"https:\/\/conseil-concurrence.preprod.io\/communique-du-conseil-de-la-concurrence-concernant-la-prise-du-controle-exclusif-de-lactivite-de-soins-de-sante-pour-les-femmes-de-la-societe-viatris-inc-par-les-societes-insud-pharma-s-l-et-2\/"},"modified":"2026-02-06T14:34:03","modified_gmt":"2026-02-06T14:34:03","slug":"statement-from-the-competition-council-regarding-the-exclusive-takeover-of-the-healthcare-activity-for-women-of-viatris-inc-by-insud-pharma-s-l-and-chemo-project-s-a-subsidiaries-of-the-insud-pharma","status":"publish","type":"post","link":"https:\/\/conseil-concurrence.ma\/en\/statement-from-the-competition-council-regarding-the-exclusive-takeover-of-the-healthcare-activity-for-women-of-viatris-inc-by-insud-pharma-s-l-and-chemo-project-s-a-subsidiaries-of-the-insud-pharma\/","title":{"rendered":"Statement from the Competition Council regarding the exclusive takeover of the healthcare activity for women of Viatris Inc by Insud Pharma S.L and Chemo Project S.A, subsidiaries of the Insud Pharma Group."},"content":{"rendered":"

Statement from the Competition Council regarding the exclusive takeover<\/strong>
\nof the healthcare activity for women of Viatris<\/strong>
\nInc by Insud Pharma S.L and Chemo Project S.A, subsidiaries of<\/strong>
\nthe Insud Pharma Group.<\/strong>
\nIn accordance with Article 13 of Law 104-12 on freedom of prices and competition
\nand Article 10 of Decree No. 2-14-652 adopted for its implementation as amended and
\nsupplemented, the Competition Council makes available to the public the ‘summary of
\nthe transaction’ below, containing the information provided by the parties.
\nThis information has been prepared by the notifying parties, who are solely responsible for it. Any inaccurate or distorted information contained therein does not in any way prejudge the Competition Council’s position on the proposed transaction.
\nThe publication of this statement does not attest to the completeness of the file provided for in
\nArticle 9 of Decree No. 2-14-652 adopted for the implementation of Law 104-12 on freedom of
\nprices and competition as amended and supplemented.
\nNames of the companies and groups involved:
\n– Insud Pharma Group;
\n– Vitaris Inc.
\nNature of the transaction
\n– Exclusive takeover.
\nEconomic sectors concerned
\n– Pharmaceutical industry sector.
\nDeadline for interested third parties to submit their observations
\n– 10 days from the date of publication of this statement, i.e. December 4,
\n2023.
\nNON-CONFIDENTIAL SUMMARY OF THE TRANSACTION PROVIDED BY THE PARTIES
\nThe Competition Council received a notification regarding the exclusive takeover of
\nthe healthcare activity for women of Viatris Inc by Insud Pharma S.L and Chemo Project S.A, subsidiaries of the Insud Pharma Group.
\nThe activities of the companies involved are as follows:
\n– Insud Pharma Group is a pharmaceutical group headquartered in Madrid, Spain, and operating in over 50 countries. This group is present in Morocco through a subsidiary named “Althea”;
\n– Vitaris Inc is an international pharmaceutical and healthcare company headquartered in the United States (Delaware).
\nDone in Rabat on November 23, 2023.<\/p>\n","protected":false},"excerpt":{"rendered":"

Statement from the Competition Council regarding the exclusive takeover of the healthcare activity for women of Viatris Inc by Insud Pharma S.L and Chemo Project S.A, subsidiaries of the Insud Pharma Group. In accordance with Article 13 of Law 104-12 on freedom of prices and competition and Article 10 of Decree No. 2-14-652 adopted for its implementation as amended and supplemented, the Competition Council makes available to the public the ‘summary of the transaction’ below, containing the information provided by the parties. This information has been prepared by the notifying parties, who are solely responsible for it. Any inaccurate or distorted information contained therein does not in any way prejudge the Competition Council’s position on the proposed transaction. The publication of this statement does not attest to the completeness of the file provided for in Article 9 of Decree No. 2-14-652 adopted for the implementation of Law 104-12 on freedom of prices and competition as amended and supplemented. Names of the companies and groups involved: – Insud Pharma Group; – Vitaris Inc. Nature of the transaction – Exclusive takeover. Economic sectors concerned – Pharmaceutical industry sector. Deadline for interested third parties to submit their observations – 10 days from the date of publication of this statement, i.e. December 4, 2023. NON-CONFIDENTIAL SUMMARY OF THE TRANSACTION PROVIDED BY THE PARTIES The Competition Council received a notification regarding the exclusive takeover of the healthcare activity for women of Viatris Inc by Insud Pharma S.L and Chemo Project S.A, subsidiaries of the Insud Pharma Group. The activities of the companies involved are as follows: – Insud Pharma Group is a pharmaceutical group headquartered in Madrid, Spain, and operating in over 50 countries. This group is present in Morocco through a subsidiary named “Althea”; – Vitaris Inc is an international pharmaceutical and healthcare company headquartered in the United States (Delaware). Done in Rabat on November 23, 2023.<\/p>\n","protected":false},"author":5,"featured_media":34707,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[352],"tags":[383],"class_list":["post-41865","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-releases","tag-2023-en"],"acf":[],"yoast_head":"\nStatement from the Competition Council regarding the exclusive takeover of the healthcare activity for women of Viatris Inc by Insud Pharma S.L and Chemo Project S.A, subsidiaries of the Insud Pharma Group. - Conseil de la concurrence du Maroc<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/conseil-concurrence.ma\/en\/statement-from-the-competition-council-regarding-the-exclusive-takeover-of-the-healthcare-activity-for-women-of-viatris-inc-by-insud-pharma-s-l-and-chemo-project-s-a-subsidiaries-of-the-insud-pharma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Statement from the Competition Council regarding the exclusive takeover of the healthcare activity for women of Viatris Inc by Insud Pharma S.L and Chemo Project S.A, subsidiaries of the Insud Pharma Group. - Conseil de la concurrence du Maroc\" \/>\n<meta property=\"og:description\" content=\"Statement from the Competition Council regarding the exclusive takeover of the healthcare activity for women of Viatris Inc by Insud Pharma S.L and Chemo Project S.A, subsidiaries of the Insud Pharma Group. In accordance with Article 13 of Law 104-12 on freedom of prices and competition and Article 10 of Decree No. 2-14-652 adopted for its implementation as amended and supplemented, the Competition Council makes available to the public the ‘summary of the transaction’ below, containing the information provided by the parties. This information has been prepared by the notifying parties, who are solely responsible for it. Any inaccurate or distorted information contained therein does not in any way prejudge the Competition Council’s position on the proposed transaction. The publication of this statement does not attest to the completeness of the file provided for in Article 9 of Decree No. 2-14-652 adopted for the implementation of Law 104-12 on freedom of prices and competition as amended and supplemented. Names of the companies and groups involved: – Insud Pharma Group; – Vitaris Inc. Nature of the transaction – Exclusive takeover. Economic sectors concerned – Pharmaceutical industry sector. Deadline for interested third parties to submit their observations – 10 days from the date of publication of this statement, i.e. December 4, 2023. NON-CONFIDENTIAL SUMMARY OF THE TRANSACTION PROVIDED BY THE PARTIES The Competition Council received a notification regarding the exclusive takeover of the healthcare activity for women of Viatris Inc by Insud Pharma S.L and Chemo Project S.A, subsidiaries of the Insud Pharma Group. The activities of the companies involved are as follows: – Insud Pharma Group is a pharmaceutical group headquartered in Madrid, Spain, and operating in over 50 countries. This group is present in Morocco through a subsidiary named “Althea”; – Vitaris Inc is an international pharmaceutical and healthcare company headquartered in the United States (Delaware). Done in Rabat on November 23, 2023.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/conseil-concurrence.ma\/en\/statement-from-the-competition-council-regarding-the-exclusive-takeover-of-the-healthcare-activity-for-women-of-viatris-inc-by-insud-pharma-s-l-and-chemo-project-s-a-subsidiaries-of-the-insud-pharma\/\" \/>\n<meta property=\"og:site_name\" content=\"Conseil de la concurrence du Maroc\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-23T16:52:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-06T14:34:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/conseil-concurrence.ma\/wp-content\/uploads\/2026\/01\/commission_permanente-4.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1170\" \/>\n\t<meta property=\"og:image:height\" content=\"486\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Youssef OTMANE\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Youssef OTMANE\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/statement-from-the-competition-council-regarding-the-exclusive-takeover-of-the-healthcare-activity-for-women-of-viatris-inc-by-insud-pharma-s-l-and-chemo-project-s-a-subsidiaries-of-the-insud-pharma\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/statement-from-the-competition-council-regarding-the-exclusive-takeover-of-the-healthcare-activity-for-women-of-viatris-inc-by-insud-pharma-s-l-and-chemo-project-s-a-subsidiaries-of-the-insud-pharma\\\/\"},\"author\":{\"name\":\"Youssef OTMANE\",\"@id\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/#\\\/schema\\\/person\\\/24b4bd1e24ccf3057c8fcb57662a0b81\"},\"headline\":\"Statement from the Competition Council regarding the exclusive takeover of the healthcare activity for women of Viatris Inc by Insud Pharma S.L and Chemo Project S.A, subsidiaries of the Insud Pharma Group.\",\"datePublished\":\"2023-11-23T16:52:10+00:00\",\"dateModified\":\"2026-02-06T14:34:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/statement-from-the-competition-council-regarding-the-exclusive-takeover-of-the-healthcare-activity-for-women-of-viatris-inc-by-insud-pharma-s-l-and-chemo-project-s-a-subsidiaries-of-the-insud-pharma\\\/\"},\"wordCount\":346,\"image\":{\"@id\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/statement-from-the-competition-council-regarding-the-exclusive-takeover-of-the-healthcare-activity-for-women-of-viatris-inc-by-insud-pharma-s-l-and-chemo-project-s-a-subsidiaries-of-the-insud-pharma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/conseil-concurrence.ma\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/commission_permanente-4.jpg\",\"keywords\":[\"2023\"],\"articleSection\":[\"Press Releases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/statement-from-the-competition-council-regarding-the-exclusive-takeover-of-the-healthcare-activity-for-women-of-viatris-inc-by-insud-pharma-s-l-and-chemo-project-s-a-subsidiaries-of-the-insud-pharma\\\/\",\"url\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/statement-from-the-competition-council-regarding-the-exclusive-takeover-of-the-healthcare-activity-for-women-of-viatris-inc-by-insud-pharma-s-l-and-chemo-project-s-a-subsidiaries-of-the-insud-pharma\\\/\",\"name\":\"Statement from the Competition Council regarding the exclusive takeover of the healthcare activity for women of Viatris Inc by Insud Pharma S.L and Chemo Project S.A, subsidiaries of the Insud Pharma Group. - Conseil de la concurrence du Maroc\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/statement-from-the-competition-council-regarding-the-exclusive-takeover-of-the-healthcare-activity-for-women-of-viatris-inc-by-insud-pharma-s-l-and-chemo-project-s-a-subsidiaries-of-the-insud-pharma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/statement-from-the-competition-council-regarding-the-exclusive-takeover-of-the-healthcare-activity-for-women-of-viatris-inc-by-insud-pharma-s-l-and-chemo-project-s-a-subsidiaries-of-the-insud-pharma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/conseil-concurrence.ma\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/commission_permanente-4.jpg\",\"datePublished\":\"2023-11-23T16:52:10+00:00\",\"dateModified\":\"2026-02-06T14:34:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/#\\\/schema\\\/person\\\/24b4bd1e24ccf3057c8fcb57662a0b81\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/statement-from-the-competition-council-regarding-the-exclusive-takeover-of-the-healthcare-activity-for-women-of-viatris-inc-by-insud-pharma-s-l-and-chemo-project-s-a-subsidiaries-of-the-insud-pharma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/statement-from-the-competition-council-regarding-the-exclusive-takeover-of-the-healthcare-activity-for-women-of-viatris-inc-by-insud-pharma-s-l-and-chemo-project-s-a-subsidiaries-of-the-insud-pharma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/statement-from-the-competition-council-regarding-the-exclusive-takeover-of-the-healthcare-activity-for-women-of-viatris-inc-by-insud-pharma-s-l-and-chemo-project-s-a-subsidiaries-of-the-insud-pharma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/conseil-concurrence.ma\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/commission_permanente-4.jpg\",\"contentUrl\":\"https:\\\/\\\/conseil-concurrence.ma\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/commission_permanente-4.jpg\",\"width\":1170,\"height\":486},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/statement-from-the-competition-council-regarding-the-exclusive-takeover-of-the-healthcare-activity-for-women-of-viatris-inc-by-insud-pharma-s-l-and-chemo-project-s-a-subsidiaries-of-the-insud-pharma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Statement from the Competition Council regarding the exclusive takeover of the healthcare activity for women of Viatris Inc by Insud Pharma S.L and Chemo Project S.A, subsidiaries of the Insud Pharma Group.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/\",\"name\":\"Conseil de la concurrence du Maroc\",\"description\":\"Conseil de la concurrence\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/#\\\/schema\\\/person\\\/24b4bd1e24ccf3057c8fcb57662a0b81\",\"name\":\"Youssef OTMANE\",\"url\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Statement from the Competition Council regarding the exclusive takeover of the healthcare activity for women of Viatris Inc by Insud Pharma S.L and Chemo Project S.A, subsidiaries of the Insud Pharma Group. - Conseil de la concurrence du Maroc","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/conseil-concurrence.ma\/en\/statement-from-the-competition-council-regarding-the-exclusive-takeover-of-the-healthcare-activity-for-women-of-viatris-inc-by-insud-pharma-s-l-and-chemo-project-s-a-subsidiaries-of-the-insud-pharma\/","og_locale":"en_US","og_type":"article","og_title":"Statement from the Competition Council regarding the exclusive takeover of the healthcare activity for women of Viatris Inc by Insud Pharma S.L and Chemo Project S.A, subsidiaries of the Insud Pharma Group. - Conseil de la concurrence du Maroc","og_description":"Statement from the Competition Council regarding the exclusive takeover of the healthcare activity for women of Viatris Inc by Insud Pharma S.L and Chemo Project S.A, subsidiaries of the Insud Pharma Group. In accordance with Article 13 of Law 104-12 on freedom of prices and competition and Article 10 of Decree No. 2-14-652 adopted for its implementation as amended and supplemented, the Competition Council makes available to the public the ‘summary of the transaction’ below, containing the information provided by the parties. This information has been prepared by the notifying parties, who are solely responsible for it. Any inaccurate or distorted information contained therein does not in any way prejudge the Competition Council’s position on the proposed transaction. The publication of this statement does not attest to the completeness of the file provided for in Article 9 of Decree No. 2-14-652 adopted for the implementation of Law 104-12 on freedom of prices and competition as amended and supplemented. Names of the companies and groups involved: – Insud Pharma Group; – Vitaris Inc. Nature of the transaction – Exclusive takeover. Economic sectors concerned – Pharmaceutical industry sector. Deadline for interested third parties to submit their observations – 10 days from the date of publication of this statement, i.e. December 4, 2023. NON-CONFIDENTIAL SUMMARY OF THE TRANSACTION PROVIDED BY THE PARTIES The Competition Council received a notification regarding the exclusive takeover of the healthcare activity for women of Viatris Inc by Insud Pharma S.L and Chemo Project S.A, subsidiaries of the Insud Pharma Group. The activities of the companies involved are as follows: – Insud Pharma Group is a pharmaceutical group headquartered in Madrid, Spain, and operating in over 50 countries. This group is present in Morocco through a subsidiary named “Althea”; – Vitaris Inc is an international pharmaceutical and healthcare company headquartered in the United States (Delaware). Done in Rabat on November 23, 2023.","og_url":"https:\/\/conseil-concurrence.ma\/en\/statement-from-the-competition-council-regarding-the-exclusive-takeover-of-the-healthcare-activity-for-women-of-viatris-inc-by-insud-pharma-s-l-and-chemo-project-s-a-subsidiaries-of-the-insud-pharma\/","og_site_name":"Conseil de la concurrence du Maroc","article_published_time":"2023-11-23T16:52:10+00:00","article_modified_time":"2026-02-06T14:34:03+00:00","og_image":[{"width":1170,"height":486,"url":"https:\/\/conseil-concurrence.ma\/wp-content\/uploads\/2026\/01\/commission_permanente-4.jpg","type":"image\/jpeg"}],"author":"Youssef OTMANE","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Youssef OTMANE","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/conseil-concurrence.ma\/en\/statement-from-the-competition-council-regarding-the-exclusive-takeover-of-the-healthcare-activity-for-women-of-viatris-inc-by-insud-pharma-s-l-and-chemo-project-s-a-subsidiaries-of-the-insud-pharma\/#article","isPartOf":{"@id":"https:\/\/conseil-concurrence.ma\/en\/statement-from-the-competition-council-regarding-the-exclusive-takeover-of-the-healthcare-activity-for-women-of-viatris-inc-by-insud-pharma-s-l-and-chemo-project-s-a-subsidiaries-of-the-insud-pharma\/"},"author":{"name":"Youssef OTMANE","@id":"https:\/\/conseil-concurrence.ma\/en\/#\/schema\/person\/24b4bd1e24ccf3057c8fcb57662a0b81"},"headline":"Statement from the Competition Council regarding the exclusive takeover of the healthcare activity for women of Viatris Inc by Insud Pharma S.L and Chemo Project S.A, subsidiaries of the Insud Pharma Group.","datePublished":"2023-11-23T16:52:10+00:00","dateModified":"2026-02-06T14:34:03+00:00","mainEntityOfPage":{"@id":"https:\/\/conseil-concurrence.ma\/en\/statement-from-the-competition-council-regarding-the-exclusive-takeover-of-the-healthcare-activity-for-women-of-viatris-inc-by-insud-pharma-s-l-and-chemo-project-s-a-subsidiaries-of-the-insud-pharma\/"},"wordCount":346,"image":{"@id":"https:\/\/conseil-concurrence.ma\/en\/statement-from-the-competition-council-regarding-the-exclusive-takeover-of-the-healthcare-activity-for-women-of-viatris-inc-by-insud-pharma-s-l-and-chemo-project-s-a-subsidiaries-of-the-insud-pharma\/#primaryimage"},"thumbnailUrl":"https:\/\/conseil-concurrence.ma\/wp-content\/uploads\/2026\/01\/commission_permanente-4.jpg","keywords":["2023"],"articleSection":["Press Releases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/conseil-concurrence.ma\/en\/statement-from-the-competition-council-regarding-the-exclusive-takeover-of-the-healthcare-activity-for-women-of-viatris-inc-by-insud-pharma-s-l-and-chemo-project-s-a-subsidiaries-of-the-insud-pharma\/","url":"https:\/\/conseil-concurrence.ma\/en\/statement-from-the-competition-council-regarding-the-exclusive-takeover-of-the-healthcare-activity-for-women-of-viatris-inc-by-insud-pharma-s-l-and-chemo-project-s-a-subsidiaries-of-the-insud-pharma\/","name":"Statement from the Competition Council regarding the exclusive takeover of the healthcare activity for women of Viatris Inc by Insud Pharma S.L and Chemo Project S.A, subsidiaries of the Insud Pharma Group. - Conseil de la concurrence du Maroc","isPartOf":{"@id":"https:\/\/conseil-concurrence.ma\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/conseil-concurrence.ma\/en\/statement-from-the-competition-council-regarding-the-exclusive-takeover-of-the-healthcare-activity-for-women-of-viatris-inc-by-insud-pharma-s-l-and-chemo-project-s-a-subsidiaries-of-the-insud-pharma\/#primaryimage"},"image":{"@id":"https:\/\/conseil-concurrence.ma\/en\/statement-from-the-competition-council-regarding-the-exclusive-takeover-of-the-healthcare-activity-for-women-of-viatris-inc-by-insud-pharma-s-l-and-chemo-project-s-a-subsidiaries-of-the-insud-pharma\/#primaryimage"},"thumbnailUrl":"https:\/\/conseil-concurrence.ma\/wp-content\/uploads\/2026\/01\/commission_permanente-4.jpg","datePublished":"2023-11-23T16:52:10+00:00","dateModified":"2026-02-06T14:34:03+00:00","author":{"@id":"https:\/\/conseil-concurrence.ma\/en\/#\/schema\/person\/24b4bd1e24ccf3057c8fcb57662a0b81"},"breadcrumb":{"@id":"https:\/\/conseil-concurrence.ma\/en\/statement-from-the-competition-council-regarding-the-exclusive-takeover-of-the-healthcare-activity-for-women-of-viatris-inc-by-insud-pharma-s-l-and-chemo-project-s-a-subsidiaries-of-the-insud-pharma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/conseil-concurrence.ma\/en\/statement-from-the-competition-council-regarding-the-exclusive-takeover-of-the-healthcare-activity-for-women-of-viatris-inc-by-insud-pharma-s-l-and-chemo-project-s-a-subsidiaries-of-the-insud-pharma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/conseil-concurrence.ma\/en\/statement-from-the-competition-council-regarding-the-exclusive-takeover-of-the-healthcare-activity-for-women-of-viatris-inc-by-insud-pharma-s-l-and-chemo-project-s-a-subsidiaries-of-the-insud-pharma\/#primaryimage","url":"https:\/\/conseil-concurrence.ma\/wp-content\/uploads\/2026\/01\/commission_permanente-4.jpg","contentUrl":"https:\/\/conseil-concurrence.ma\/wp-content\/uploads\/2026\/01\/commission_permanente-4.jpg","width":1170,"height":486},{"@type":"BreadcrumbList","@id":"https:\/\/conseil-concurrence.ma\/en\/statement-from-the-competition-council-regarding-the-exclusive-takeover-of-the-healthcare-activity-for-women-of-viatris-inc-by-insud-pharma-s-l-and-chemo-project-s-a-subsidiaries-of-the-insud-pharma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/conseil-concurrence.ma\/en\/"},{"@type":"ListItem","position":2,"name":"Statement from the Competition Council regarding the exclusive takeover of the healthcare activity for women of Viatris Inc by Insud Pharma S.L and Chemo Project S.A, subsidiaries of the Insud Pharma Group."}]},{"@type":"WebSite","@id":"https:\/\/conseil-concurrence.ma\/en\/#website","url":"https:\/\/conseil-concurrence.ma\/en\/","name":"Conseil de la concurrence du Maroc","description":"Conseil de la concurrence","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/conseil-concurrence.ma\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/conseil-concurrence.ma\/en\/#\/schema\/person\/24b4bd1e24ccf3057c8fcb57662a0b81","name":"Youssef OTMANE","url":"https:\/\/conseil-concurrence.ma\/en\/"}]}},"_links":{"self":[{"href":"https:\/\/conseil-concurrence.ma\/en\/wp-json\/wp\/v2\/posts\/41865","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/conseil-concurrence.ma\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/conseil-concurrence.ma\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/conseil-concurrence.ma\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/conseil-concurrence.ma\/en\/wp-json\/wp\/v2\/comments?post=41865"}],"version-history":[{"count":1,"href":"https:\/\/conseil-concurrence.ma\/en\/wp-json\/wp\/v2\/posts\/41865\/revisions"}],"predecessor-version":[{"id":45182,"href":"https:\/\/conseil-concurrence.ma\/en\/wp-json\/wp\/v2\/posts\/41865\/revisions\/45182"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/conseil-concurrence.ma\/en\/wp-json\/wp\/v2\/media\/34707"}],"wp:attachment":[{"href":"https:\/\/conseil-concurrence.ma\/en\/wp-json\/wp\/v2\/media?parent=41865"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/conseil-concurrence.ma\/en\/wp-json\/wp\/v2\/categories?post=41865"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/conseil-concurrence.ma\/en\/wp-json\/wp\/v2\/tags?post=41865"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}